aTyr Pharma, Inc. (ATYR)
| Market Cap | 77.48M |
| Revenue (ttm) | 190,000 |
| Net Income (ttm) | -74.12M |
| Shares Out | 98.05M |
| EPS (ttm) | -0.80 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 410,971 |
| Open | 0.787 |
| Previous Close | 0.791 |
| Day's Range | 0.780 - 0.813 |
| 52-Week Range | 0.640 - 7.290 |
| Beta | 0.65 |
| Analysts | Hold |
| Price Target | 3.67 (+364.44%) |
| Earnings Date | May 1, 2026 |
About ATYR
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pn... [Read more]
Financial Performance
In 2025, aTyr Pharma's revenue was $190,000, a decrease of -19.15% compared to the previous year's $235,000. Losses were -$74.12 million, 15.8% more than in 2024.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for ATYR stock is "Hold." The 12-month stock price target is $3.67, which is an increase of 364.44% from the latest price.
News
Ethos Collaborates with Liberty Mutual to Deliver a Modern, Digital-First Life Insurance Experience
500 - Internal server error. Server Error 500 - Internal server error.
Ethos to Announce First Quarter 2026 Financial Results on May 6, 2026
AUSTIN, Texas, April 02, 2026 (GLOBE NEWSWIRE) -- Ethos Technologies Inc. (NASDAQ: LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announ...
Ethos and Banner Life Expand Offering to Bring Final Expense Coverage to More Families
AUSTIN, Texas and FREDERICK, Md., March 24, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced an expansi...
aTyr Pharma Transcript: Leerink Global Healthcare Conference 2026
Efzofitimod demonstrated strong trends in steroid reduction and significant, durable quality of life improvements in sarcoidosis, though the primary endpoint was not met due to high placebo response. The upcoming FDA meeting will clarify the regulatory path, while ongoing trials in scleroderma-related ILD show early promise.
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update
Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 EFZO-CON...
Ethos to Participate in The Citizens Technology Conference
AUSTIN, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ: LIFE), a leading life insurance technology company democratizing access to life insurance, today announced that Peter Colis, Co-founder ...
Ethos Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Ethos Reports 4Q and FY2025 Financial Results, Delivers 3rd consecutive year of revenue growth greater than 50%. Records full-year revenue of $387.6 Mil.
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cla...
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its prop...
Ethos to Announce Fourth Quarter 2025 Financial Results on February 25, 2026
AUSTIN, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced that it will release its finan...
The IPO Market Faces a Busy Week. These Stocks Are Making Their Debuts.
Forgent Power Solutions, Liftoff Mobile and several consumer and biotech firms are set to go public.
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis
Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis is scheduled for mid-April 2026. SAN DIEGO, Feb. 03,...
Insurance platform Ethos Technologies valued at $1.2 billion in Nasdaq debut
Ethos Technologies clinched a valuation of $1.2 billion in its Nasdaq debut on Thursday, adding to a wave of insurance companies capitalizing on buoyant investor demand.
Ethos Announces Pricing of Initial Public Offering
AUSTIN, Texas, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced the pricing of its initial pub...
Ethos Technologies prices US IPO at $19/share, Bloomberg News reports
Insurance platform Ethos Technologies priced its U.S. initial public offering at $19 per share, Bloomberg News reported on Wednesday, citing a person familiar with the matter.
Ethos and North American Collaborate to Offer Accumulation Indexed Universal Life Product
AUSTIN, Texas and DES MOINES, Iowa, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced a partner...
Ethos and Aflac Partner to Bring Supplemental Health Product Suite to Independent Distribution
Ethos announced a partnership with Aflac to expand access to Aflac's supplemental insurance policies through Ethos's digital distribution platform.
Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders
SAN DIEGO , Dec. 15, 2025 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential derivative claims on behalf of aTyr Pharma, Inc. (NASDAQ: ATYR) concerning alleged fiduciary breaches tied to ...
aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR
LOS ANGELES , Dec. 8, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of aTyr Pharma, Inc. ("aTyr" or "the Company") (NASDAQ: ATYR) for violatio...
ATYR DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired se...
ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure
Legal Focus on Drug Efficacy: Partner Reed Kathrein Scrutinizing Alleged Misrepresentations of Efzofitimod's Steroid-Tapering Capability Legal Focus on Drug Efficacy: Partner Reed Kathrein Scrutinizin...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired se...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 8, 2025 in aTyr Lawsuit – ATYR
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of aTyr Pharma, Inc. (NASDAQ: ATYR).
ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options
aTyr Pharma Transcript: Piper Sandler 37th Annual Healthcare Conference
Full EFZO-FIT results showed strong steroid reduction and quality of life improvements, with experts viewing the data as clinically meaningful. The team is preparing for an FDA meeting in Q1 2026, ready for multiple regulatory scenarios, and expects further data from the EFZO-CONNECT study later this year.